Zacks Investment Research Lowers Vivos Therapeutics (NASDAQ:VVOS) to Hold


Share on StockTwits

Zacks Investment Research cut shares of Vivos Therapeutics (NASDAQ:VVOS) from a buy rating to a hold rating in a research note released on Wednesday, Zacks.com reports.

According to Zacks, “Vivos Therapeutics Inc. is a medical technology company. It engages in the development and commercialization of technology solutions for patients with sleep disordered breathing comprising mild-to-moderate obstructive sleep apnea. Vivos Therapeutics Inc. is based in Highlands Ranch, Colorado. “

Other equities analysts also recently issued reports about the stock. Craig Hallum initiated coverage on shares of Vivos Therapeutics in a report on Monday, January 11th. They issued a buy rating and a $12.00 price target on the stock. Roth Capital started coverage on shares of Vivos Therapeutics in a report on Tuesday, January 5th. They set a buy rating and a $12.00 price objective on the stock.

Shares of NASDAQ:VVOS opened at $8.37 on Wednesday. The business has a 50-day moving average of $7.56. Vivos Therapeutics has a fifty-two week low of $5.64 and a fifty-two week high of $14.41.

Vivos Therapeutics (NASDAQ:VVOS) last issued its quarterly earnings results on Thursday, March 25th. The company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.27). The company had revenue of $3.30 million for the quarter, compared to the consensus estimate of $2.92 million.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VVOS. K.J. Harrison & Partners Inc purchased a new stake in Vivos Therapeutics during the fourth quarter valued at about $540,000. Royce & Associates LP purchased a new stake in shares of Vivos Therapeutics in the fourth quarter worth about $1,773,000. Perkins Capital Management Inc. purchased a new stake in shares of Vivos Therapeutics in the fourth quarter worth about $118,000. Walleye Capital LLC purchased a new stake in shares of Vivos Therapeutics in the fourth quarter worth about $440,000. Finally, Jane Street Group LLC purchased a new stake in shares of Vivos Therapeutics in the fourth quarter worth about $191,000.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA.

Further Reading: How are capital gains distributions different for tax-deferred account?

Get a free copy of the Zacks research report on Vivos Therapeutics (VVOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.